Liver heparan sulfate proteoglycans: Old molecules provide new insights on lipoprotein metabolism - Commentary

Hepatology

Volumn 45, Issue 4, 2007, Pages 1078-1080

  Cortés, Víctor ^a   Rigotti, Attilio ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C; APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN RECEPTOR; N ACETYLGLUCOSAMINE; PROTEOHEPARAN SULFATE; RETINOL ESTER; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

GENE INACTIVATION; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; LIVER CELL; NONHUMAN; NOTE; PRIORITY JOURNAL;

EID: 34247373762     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21647     Document Type: Note

References (17)

1. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independendy of LDL receptor family members. J Clin Invest 2007;117:153-164.
2. Mahley RW, Weisgraber KH, Innerarity TL. Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim Biophys Acta 1979;575:81-91.
3. Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem 1993;268:10160-10167.
4. Ji ZS, Sanan DA, Mahley RW. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res 1995;36:583-592.
5. Otsu K, Kato S, Ohtake K, Akamatsu N. Alteration of rat liver proteoglycans during regeneration. Arch Biochem Biophys 1992;294:544-549.
6. Roskams T, Rosenbaum J, De Vos R, David G, Desmet V. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases. HEPATOLOGY 1996;24:524-523.
7. Murata K, Ochiai Y, Akashio K. Polydispersity of acidic glycosaminoglycan components in human liver and the changes at different stages in liver cirrhosis. Gastroenterology 1985;89:1248-1257.
8. Kovalszky I, Pogany G, Molnar G, Jeney A, Lapis K, Karacsonyi S, et al. Altered glycosaminoglycan composition in reactive and neoplastic human liver. Biochem Biophys Res Commun 1990;167:883-890.
9. Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem 1994;269:13421-13428.
10. Forsberg E, Kjellen L. Heparan sulfate: lessons from knockout mice. J Clin Invest 2001;108:175-180.
11. Fuki IV, Kuhn KM, Lomazov IR, Rothman VL, Tuszynski GP, Iozzo RV, et al. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest 1997;100:1611-1622.
12. Wilsie LC, Gonzales AM, Orlando RA. Syndecan-1 mediates internalization of apoE-VLDL through a low density lipoprotein receptor-related protein (LRP)-independent, non-clathrin-mediated pathway. Lipids Health Dis 2006;5:23.
13. Zeng BJ, Mortimer BC, Martins IJ, Seydel U, Redgrave TG. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J Lipid Res 1998;39:845-860.
14. Cortes V AL, Donoso K, Valencia I, Quinones V, Zanlungo S, Brandan E, et al. Adenovirus-mediated hepatic syndecan-1 overexpression induces hepatocyte proliferation and hyperlipidemia in mice. Liver Int; in press.
15. Kjellen L, Bielefeld D, Hook M. Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 1983;32:337-342.
16. Ebara T, Conde K, Kako Y, Liu Y, Xu Y, Ramakrishnan R, et al. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 2000;105:1807-1818.
17. Anisfeld AM, Kast-Woelbern HR, Meyer ME, Jones SA, Zhang Y, Williams KJ, et al. Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. J Biol Chem 2003;278:20420-20428.